Clinical Trial Update: Vorinostat and Azacitidine in Treating Patients With Locally Recurrent or Metastatic Nasopharyngeal Cancer or Nasal Natural Killer T-Cell Lymphoma [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluating vorinostat with azacitidine in adults with nasal-type extranodal NK/T-cell lymphoma or recurrent nasopharyngeal carcinoma; the study …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Extranodal Nk T-cell Lymphoma Nasal Type
• Keratinizing Squamous Cell Carcinoma of the Nasopharynx
• Nasopharyngeal Carcinoma Undifferentiated Type

Drugs mentioned

• AZACITIDINE (AZACITIDINE)
• Vorinostat (vorinostat)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Adult Nasal Type Extranodal NK/T-Cell Lymphoma, Recurrent Nasopharyngeal Keratinizing Squamous Cell Carcinoma | Phase 1 | Status: ACTIVE_NOT_RECRUITING